PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy. EXPERIMENTAL DESIGN: This was a phase II, open-label, single center trial. On gross total resection of the tumor, up to eight Gliadel wafers were implanted. Bolus infusion of O6-BG was administered at 120 mg/m2 over 1 hour on days 1, 3, and 5, along with a continuous infusion at 30 mg/m2/d. The primary end points were 6-month overall survival (OS) and safety, and the secondary end points were 1-year, 2-year, and median OS. RESULTS: Fifty-two patients were accrued. The 6-month OS was 82% [95% confidence interval (95% CI), 72-93%]. The 1- and 2-year OS rates were 47% (95% CI, 35-63%) and 10% (95% CI, 3-32%), respectively. The median OS was 50.3 weeks (95% CI, 36.1-69.4 weeks). Treatment-related toxicity with this drug combination included grade 3 hydrocephalus (9.6%), grade 3 cerebrospinal fluid (CSF) leak (19.2%), and grade 3 CSF/brain infection (13.4%). CONCLUSION: The efficacy of implanted Gliadel wafers may be improved with the addition of O6-BG. Although systemically administered O6-BG can be coadministered with Gliadel wafers safely, it may increase the risk of hydrocephalus, CSF leak, and CSF/brain infection. Future trials are required to verify that inhibition of tumor AGT levels by O6-BG results in increased efficacy of Gliadel wafers without added toxicity.
PURPOSE: This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumorO6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy. EXPERIMENTAL DESIGN: This was a phase II, open-label, single center trial. On gross total resection of the tumor, up to eight Gliadel wafers were implanted. Bolus infusion of O6-BG was administered at 120 mg/m2 over 1 hour on days 1, 3, and 5, along with a continuous infusion at 30 mg/m2/d. The primary end points were 6-month overall survival (OS) and safety, and the secondary end points were 1-year, 2-year, and median OS. RESULTS: Fifty-two patients were accrued. The 6-month OS was 82% [95% confidence interval (95% CI), 72-93%]. The 1- and 2-year OS rates were 47% (95% CI, 35-63%) and 10% (95% CI, 3-32%), respectively. The median OS was 50.3 weeks (95% CI, 36.1-69.4 weeks). Treatment-related toxicity with this drug combination included grade 3 hydrocephalus (9.6%), grade 3 cerebrospinal fluid (CSF) leak (19.2%), and grade 3 CSF/brain infection (13.4%). CONCLUSION: The efficacy of implanted Gliadel wafers may be improved with the addition of O6-BG. Although systemically administered O6-BG can be coadministered with Gliadel wafers safely, it may increase the risk of hydrocephalus, CSF leak, and CSF/brain infection. Future trials are required to verify that inhibition of tumorAGT levels by O6-BG results in increased efficacy of Gliadel wafers without added toxicity.
Authors: Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram Journal: Neuro Oncol Date: 2003-04 Impact factor: 12.300
Authors: Jennifer A Quinn; James Pluda; M Eileen Dolan; Shannon Delaney; Richard Kaplan; Jeremy N Rich; Allan H Friedman; David A Reardon; John H Sampson; O Michael Colvin; Michael M Haglund; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: Jon Weingart; Stuart A Grossman; Kathryn A Carson; Joy D Fisher; Shannon M Delaney; Mark L Rosenblum; Alessandro Olivi; Kevin Judy; Stephen B Tatter; M Eileen Dolan Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: H S Friedman; J Pluda; J A Quinn; R B Ewesuedo; L Long; A H Friedman; I Cokgor; O M Colvin; M M Haglund; D M Ashley; J N Rich; J Sampson; A E Pegg; R C Moschel; R E McLendon; J M Provenzale; E S Stewart; S Tourt-Uhlig; A M Garcia-Turner; J E Herndon; D D Bigner; M E Dolan Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: S Clifford Schold; Demetrius M Kokkinakis; Susan M Chang; Mitchel S Berger; Kenneth R Hess; David Schiff; H Ian Robins; Minesh P Mehta; Karen L Fink; R L Davis; Michael D Prados Journal: Neuro Oncol Date: 2004-01 Impact factor: 12.300
Authors: S C Schold; T P Brent; E von Hofe; H S Friedman; S Mitra; D D Bigner; J A Swenberg; P Kleihues Journal: J Neurosurg Date: 1989-04 Impact factor: 5.115
Authors: Monika E Hegi; Annie-Claire Diserens; Sophie Godard; Pierre-Yves Dietrich; Luca Regli; Sandrine Ostermann; Philippe Otten; Guy Van Melle; Nicolas de Tribolet; Roger Stupp Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Ganesan Vaidyanathan; Benjamin White; Donna J Affleck; Darryl McDougald; Michael R Zalutsky Journal: Nucl Med Biol Date: 2010-10-27 Impact factor: 2.408
Authors: A Gutenberg; C B Lumenta; W E K Braunsdorf; M Sabel; H M Mehdorn; M Westphal; A Giese Journal: J Neurooncol Date: 2013-03-28 Impact factor: 4.130